IPHA Innate Pharma |
$1.03 -22.9% |
-29.8%
 |
IPH4502
Topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
|
Phase 1
|
11/18/2026 - Initial Data
Innate Pharma SA announced initial Phase 1 data from its ongoing study of IPH4502, an investigationa… Full Summary
|
RXRX Recursion Pharmaceuticals |
$2.94 +8.0% |
-18.6%
 |
REC-4881
Familial Adenomatous Polyposis (FAP)
|
Phase 3
|
11/18/2026 - Provided Update
Recursion announced that it has aligned with the FDA on the design of its registrational Phase 3 tri… Full Summary
|
SMMT Summit Therapeutics |
$10.65 -0.2% |
-31.6%
 |
Ivonescimab
For Lung cancer
|
Phase 3
|
11/18/2026 - Initiation
Summit Therapeutics Inc. announced the initiation of a new global Phase III clinical trial of ivone… Full Summary
|
NBP Novabridge Biosciences |
$0.88 +6.5% |
-32.6%
 |
VIS-101
in patients with wet age-related macular degeneration (wet AMD).
|
Phase 2b
|
11/18/2026 - Dose Update
Visara, Inc subsidiary of NovaBridge Biosciences, Inc. announced that the first patient has been d… Full Summary
|
OPTH Optimi Health |
$1.99 -5.2% |
-40.2%
 |
OPTI-201
in Major Depressive Disorder
|
|
11/18/2026 - Provided Update
Optimi Health Corp provides an update on its clinical programs, commercial supply, Ibogaine Initiati… Full Summary
|
IMRX Immuneering |
$3.56 +2.7% |
-2.9%
 |
Atebimetinib
in Pancreatic Cancer
|
|
11/18/2026 - Findings Update
Immuneering Corporation announced compelling preclinical data that supports expanding the clinical d… Full Summary
|
IONS Ionis Pharmaceuticals |
$27.59 +2.3% |
-37.8%
 |
Olezarsen (Formerly IONIS-APOCIII-L)
Severe hypertriglyceridemia
|
EC Approval
|
11/17/2026 - Approved
Ionis Pharmaceuticals, Inc. announced that the European Commission (EC) has approved TRYNGOLZA™ (ol… Full Summary
|
EIKN Eikon Therapeutics |
$5.31 +3.1% |
-31.0%
 |
EIK1006
in Advanced Metastatic Prostate Cancer
|
IND
|
11/17/2026 - FDA Clearance
ikon Therapeutics, announced U.S. Food and Drug Administration clearance to proceed for the Invest… Full Summary
|
EIKN Eikon Therapeutics |
$5.31 +3.1% |
-31.0%
 |
EIK1006
in Advanced Metastatic Prostate Cancer
|
Phase 1/2 Target date: H2 2027
|
11/17/2026 - Initial Data
Eikon Therapeutics, Inc. announced that Initial clinical data from Phase 1/2 study expected in sec… Full Summary
|
MDT Medtronic |
$101.10 -1.2% |
+8.9%
 |
Hugo
for gynecological procedures
|
|
11/17/2026 - FDA Clearance
Medtronic plc announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-as… Full Summary
|
REGN Regeneron Pharmaceuticals |
$951.41 -0.7% |
+21.7%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
EC Approval
|
11/17/2026 - Approved
Regeneron Pharmaceuticals, Inc announced that the European Commission (EC) has approved an alternat… Full Summary
|
SNY Sanofi |
$47.35 -0.4% |
+19.7%
 |
Libtayo (cemiplimab)
Advanced Cervical Cancer
|
EC Approval
|
11/17/2026 - Approved
Regeneron Pharmaceuticals, Inc announced that the European Commission (EC) has approved an alternat… Full Summary
|
SLS SELLAS Life Sciences Group |
$19.98 +4.4% |
+90.5%
 |
galinpepimut-S (GPS)
Targets the WT1 protein, which is present in an array of tumor types.
|
|
11/17/2026 - Top-line results
SELLAS Life Sciences Group, Inc. announced positive topline results from the pivotal randomized Phas… Full Summary
|
LUNG Pulmonx |
$2.73 -0.2% |
+55.7%
 |
AeriSeal
For bronchoscopic lung volume reduction (BLVR) and block collateral ventilation.
|
|
11/17/2026 - Publication
Pulmonx Corporation announced the online publication of results from the CONVERT Trial evaluating t… Full Summary
|
VERU Veru |
$2.30 +7.5% |
-0.4%
 |
Enobosarm
ER+/HER2- breast cancer
|
|
11/17/2026 - Presentation
Veru Inc. announced that Veru had a podium presentation at ObesityWeek 2026 in Washington DC. Full Summary
|
ACAD ACADIA Pharmaceuticals |
$18.16 -0.9% |
-8.3%
 |
Remlifanserin
Treatment Of Hallucinations And Delusions Associated With Alzheimer’s Disease Psychosis
|
|
11/17/2026 - Additional data
Acadia Pharmaceuticals Inc today presented additional data from the Phase 2 RADIANT trial evaluating… Full Summary
|
NUVL Nuvalent |
$123.96
|
|
neladalkib
advanced ALK-positive solid tumors outside of non-small cell lung cancer (NSCLC).
|
|
11/17/2026 - Approved
GSK plc announced the US Food and Drug Administration (FDA) has granted accelerated approval to Nelk… Full Summary
|
BIIB Biogen |
$251.98 +0.5% |
+7.9%
 |
diranersen
Alzheimer’s disease
|
|
11/17/2026 - New Data
Biogen Inc. announced new data from the Phase 2 CELIA study showing increasing clinical benefit of d… Full Summary
|
GANX Gain Therapeutics |
$1.18 -0.4% |
-6.0%
 |
rexaceract
Parkinson’s Disease and Related Disorders
|
Phase 1b
|
11/17/2026 - Late Breaking Presentation
Gain Therapeutics, Inc. announced the late-breaking presentation of clinical data from the Phase 1… Full Summary
|
ACRS Aclaris Therapeutics |
$3.46 +2.2% |
-0.7%
 |
ATI-045
In Atopic Dermatitis (AD)
|
Phase 2
|
11/16/2026 - Top-line results
Aclaris Therapeutics, Inc. announced top line results from the Phase 2 ADMIRATION trial that evaluat… Full Summary
|
ACRS Aclaris Therapeutics |
$3.46 +2.2% |
-0.7%
 |
ATI-2138
For the Treatment of Moderate to Severe Atopic Dermatitis
|
Phase 2b
|
11/16/2026 - Initiation
Aclaris Therapeutics, Inc. announced initiation of its randomized, double-blind, placebo-controlled… Full Summary
|
CYTK Cytokinetics |
$51.55 -0.2% |
-17.7%
 |
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
|
supplemental New Drug Application (sNDA)
|
11/16/2026 - FDA approved
Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved … Full Summary
|
HELP Cybin |
$6.81 -5.5% |
-36.3%
 |
HLP003
adjunctive treatment of major depressive disorder ("MDD")
|
Phase 3
|
11/16/2026 - Top-line results
Helus Pharma Inc. announced positive topline results from APPROACH, its Phase 3 pivotal study evalua… Full Summary
|
CRDF Cardiff Oncology |
$0.85 +0.9% |
-3.6%
 |
onvansertib
in Chronic Myelomonocytic Leukemia
|
Fast Track
|
11/16/2026 - Designation Grant
Cardiff Oncology, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast T… Full Summary
|
RNTX Rein Therapeutics |
$0.37 +4.1% |
-32.8%
 |
LTI-03
In Idiopathic Pulmonary Fibrosis
|
Phase 2
|
11/16/2026 - Observations
Rein Therapeutics announced preliminary blinded twelve-week observations from the ongoing RENEW Phas… Full Summary
|
RADX Radiopharm Theranostics |
$0.71 +6.0% |
-32.2%
 |
RAD101
patients with indeterminate brain metastases following radiotherapy.
|
Phase 2b
|
11/16/2026 - Data
Radiopharm Theranostics announced that data from the Phase 2b imaging study of RAD101 in suspected … Full Summary
|
BIVI BioVie |
$0.98 -1.5% |
-28.5%
 |
Bezisterim
For Parkinson's Disease Patients
|
Phase 2
|
11/16/2026 - Findings Update
BioVie Inc. announced new clinical and biomarker findings from the Phase 2 ADDRESS-LC trial of bezis… Full Summary
|
CRBP Corbus Pharmaceuticals |
$2.67 -11.3% |
-40.1%
 |
CRB-913
For Obesity
|
|
11/16/2026 - Additional data
Corbus Pharmaceuticals Holdings, Inc announced today that additional data from the CANYON-1 Phase 1… Full Summary
|
ESLA Estrella Immunopharma |
$0.37 +11.9% |
-2.3%
 |
ARTEMIS T
for cancer and autoimmune diseases
|
|
11/16/2026 - Findings Update
Estrella Immunopharma, Inc. today highlighted preclinical findings from an abstract accepted for po… Full Summary
|
MDWD MediWound |
$13.90 +1.6% |
+9.4%
 |
EscharEx
Chronic Wounds
|
|
11/16/2026 - Provided Update
MediWound Ltd. announced that it will host a virtual Key Opinion Leader (KOL) event on Wednesday, De… Full Summary
|
NUVB Nuvation Bio |
$3.92 +0.4% |
-12.7%
 |
Safusidenib
Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology
|
Phase 2
|
11/16/2026 - Follow-up data
Nuvation Bio Inc. announced new long-term follow-up data from the Phase 2 (J201) study of investiga… Full Summary
|
LNTH Lantheus |
$101.81 +0.0% |
+1.9%
 |
TAUKLARIFY
PET Imaging in Early Alzheimer’s Disease
|
Phase 3
|
11/16/2026 - Results
Lantheus Holdings, Inc. announced results from two pivotal Phase 3 studies evaluating the diagnostic… Full Summary
|
IDYA IDEAYA Biosciences |
$26.41 -3.6% |
-21.9%
 |
IDE849
In Solid Tumors
|
|
11/16/2026 - Provided Update
IDEAYA Biosciences, Inc. announced its registrational strategy for IDE849, a potential best-in-clas… Full Summary
|
IDYA IDEAYA Biosciences |
$26.41 -3.6% |
-21.9%
 |
IDE101
Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors
|
|
11/15/2026 - Provided Update
IDEAYA Biosciences, Inc announced development candidate nomination of IDE101, a potential first-in-c… Full Summary
|
DRTS Alpha Tau Medical |
$12.13 +0.4% |
-3.9%
 |
Alpha DaRT
Prostate cancer
|
|
11/15/2026 - Results
Alpha Tau Medical Ltd. announced updated interim results from its U.S. REGAIN (Recurrent Glioblast… Full Summary
|
VKTX Viking Therapeutics |
$26.90 +0.1% |
+7.4%
 |
VK2735
Metabolic disorders
|
|
11/15/2026 - Poster Presentation
Viking Therapeutics, Inc announced that new clinical data from the company's VK2735 obesity program… Full Summary
|
HELP Cybin |
$6.81 -5.5% |
-36.3%
 |
HLP003
adjunctive treatment of major depressive disorder ("MDD")
|
|
11/15/2026 - Provided Update
Helus Pharma Inc. announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline… Full Summary
|
RZLT Rezolute |
$4.07 +1.5% |
+10.1%
 |
Ersodetug
For Hypoglycemia Due to Congenital Hyperinsulinism
|
Phase 3
|
11/13/2026 - Positive Results
Rezolute, Inc. announced positive results from the ongoing open-label Phase 3 upLIFT study of ersode… Full Summary
|
MRK Merck & Co., Inc. |
$138.97 -3.1% |
-3.2%
 |
belzutifan
Treated Patients With Advanced Renal Cell Carcinoma (RCC)
|
EMA
|
11/13/2026 - Positive Opinion
Merck announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP… Full Summary
|
MRK Merck & Co., Inc. |
$138.97 -3.1% |
-3.2%
 |
ENFLONSIA™
In Infants Born During or Entering Their First RSV Season
|
|
11/13/2026 - Positive Opinion
Merck announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European… Full Summary
|
ZLAB Zai Lab |
$22.41 -4.7% |
-6.8%
 |
ZL-1503
For the Treatment of Atopic Dermatitis
|
Phase 1/1b
|
11/13/2026 - Preliminary Results
Zai Lab Limited announced positive preliminary, first-in-human results from the single-ascending-dos… Full Summary
|
BCRX BioCryst Pharmaceuticals |
$7.49 -0.2% |
-7.2%
 |
ORLADEYO (berotralstat)
Hereditary angioedema (HAE)
|
|
11/13/2026 - Provided Update
BioCryst Pharmaceuticals, Inc. announced new real-world evidence on the use of once-daily ORLADEYO… Full Summary
|
WVE WAVE Life Sciences |
$2.84 -0.2% |
-10.6%
 |
WVE-007
For obesity.
|
|
11/13/2026 - Highlights
Wave Life Sciences, today highlights WVE-007 progress at ObesityWeek®, the annual congress of The O… Full Summary
|
ARGX argenex |
$946.12 -0.1% |
+14.6%
 |
VYVGART Hytrulo
Injection for Subcutaneous Use in Generalized Myasthenia Gravis
|
|
11/13/2026 - Provided Update
Zai Lab Limited announced that five of its commercial medicines in China have been included in the… Full Summary
|
ALT Altimmune |
$1.43 -6.9% |
-36.1%
 |
pemvidutide
for the treatment of obesity and MASH
|
|
11/12/2026 - Publication
Altimmune, Inc. announced the publication of 48-week results from the IMPACT Phase 2b trial of pemv… Full Summary
|
IMRX Immuneering |
$3.56 +2.7% |
-2.9%
 |
Atebimetinib
in Pancreatic Cancer
|
Phase 2
|
11/12/2026 - Initiation
Immuneering Corporation announced plans to initiate a Phase 2 clinical trial evaluating atebimetin… Full Summary
|
TAK Takeda Pharmaceutical |
$21.40 -1.1% |
+9.1%
 |
ORZEYFUL
treatment of narcolepsy type 1
|
|
11/12/2026 - Provided Update
Takeda announced that ORZEYFUL™ (oveporexton) CIV is now available in the U.S. by prescription for t… Full Summary
|
DRTS Alpha Tau Medical |
$12.13 +0.4% |
-3.9%
 |
Alpha DaRT
Prostate cancer
|
|
11/12/2026 - Provided Update
Alpha Tau Medical Ltd. announced that it will host a conference call and webcast on Monday, Nov. 16… Full Summary
|
IMMP Prima BioMed |
$3.29 +0.8% |
+3.6%
 |
eftilagimod alpha
For cancer and autoimmune disease
|
|
11/11/2026 - Survival data
Immutep Limited announced the release of an abstract reporting interim disease-free survival data a… Full Summary
|
BBIO BridgeBio Pharma |
$77.92 +1.5% |
+14.7%
 |
ATTR-CM
first-line treatment of choice for individuals with ATTR-CM
|
|
11/11/2026 - Abstract
BridgeBio Pharma, Inc. announced 28 abstracts on acoramidis in individuals with transthyretin amylo… Full Summary
|
GH Guardant Health |
$145.97 +1.9% |
-7.5%
 |
Guardant360
Advanced solid tumors.
|
|
11/11/2026 - Provided Update
Guardant Health, Inc. announced new applications for Guardant360® Liquid designed to help oncologis… Full Summary
|
VNDA Vanda Pharmaceuticals |
$3.85 +0.9% |
-6.0%
 |
Tradipitant
Tradipitant is a neurokinin-1 receptor antagonist
|
|
11/11/2026 - Provided Update
Vanda Pharmaceuticals Inc. announced that "NEREUS™ – The Goat of Biscayne Bay" is arriving during M… Full Summary
|
LLY Eli Lilly and Company |
$1,392.09 -1.7% |
+12.0%
 |
Taltz
adults with psoriasis and obesity or overweight
|
Phase 3
|
11/11/2026 - Results
Eli Lilly and Company announced detailed 52-week results showing improved and durable efficacy fro… Full Summary
|
CHRS Coherus Oncology |
$0.42 -12.0% |
-56.1%
 |
toripalimab-tpzi
in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)
|
|
11/11/2026 - Provided Update
Oncolytics Biotech® Inc. announced today that it has entered into a clinical supply agreement with… Full Summary
|
ENGN enGene |
$1.90 +10.2% |
+19.9%
 |
detalimogene voraplasmid
in BCG-Unresponsive NMIBC
|
Phase 2
|
11/11/2026 - updated results
enGene Therapeutics Inc. announced updated results from the pivotal Cohort 1 of its ongoing, Phase… Full Summary
|
BDTX Black Diamond Therapeutics |
$1.41 -2.4% |
-22.4%
 |
silevertinib
patients with cancer
|
Phase 2
|
11/10/2026 - Updated data
Black Diamond Therapeutics, Inc today reported updated data from its Phase 2 trial of silevertinib … Full Summary
|
FATE Fate Therapeutics |
$1.08 +5.4% |
-42.2%
 |
FT819
Advanced B-cell Leukemias and Lymphomas
|
|
11/10/2026 - Updated data
Fate Therapeutics, Inc. announced that updated clinical data for FT819, together with translational … Full Summary
|
BMEA Biomea Fusion |
$0.49 -0.6% |
-42.0%
 |
BMF-650
GLP-1 receptor agonist
|
|
11/10/2026 - Presentation
Biomea Fusion, Inc. announced that it will present Phase 1 clinical results for BMF-650, its investi… Full Summary
|
BEAM Beam Therapeutics |
$21.81 +5.6% |
-9.8%
 |
risto-cel
sickle cell disease
|
|
11/10/2026 - Top-line results
- Beam Therapeutics Inc. announced positive topline results from the BEACON Phase 1/2 study evaluat… Full Summary
|
CTY City Therapeutics |
$17.41 -0.5% |
-18.9%
 |
CITY-RBP4
Treatment of Stargardt Disease
|
Phase 1
|
11/10/2026 - Dose Update
City Therapeutics, Inc. announced that the first participant has been dosed in the Phase 1 clinical… Full Summary
|
KLRA Kailera Therapeutics |
$12.25 +0.4% |
+7.2%
 |
ribupatide
GLP-1/GIP/glucagon receptor tri-agonist in obesity.
|
|
11/10/2026 - Presentation
- Kailera Therapeutics, Inc announced that new clinical and real-world research will be presented a… Full Summary
|
MIRM Mirum Pharmaceuticals |
$92.16 +0.2% |
+12.1%
 |
brelovitug
treatment of chronic hepatitis delta virus (HDV)
|
Phase 3
|
11/10/2026 - Endpoint Met
Mirum Pharmaceuticals, Inc announced that the primary endpoint was met in the Phase 3 AZURE-4 study… Full Summary
|
CING Cingulate |
$5.12 +8.5% |
+17.4%
 |
CTx-1301
Attention Deficit/Hyperactivity Disorder (ADHD)
|
|
11/10/2026 - Regulatory Update
Cingulate Inc. announced today that Chairman and CEO Shane J. Schaffer has provided an update on th… Full Summary
|
BIVI BioVie |
$0.98 -1.5% |
-28.5%
 |
Bezisterim
For Parkinson's Disease Patients
|
|
11/10/2026 - Oral presentation
BioVie Inc. announced the Company has been invited to present two oral presentations at the AD/PD202… Full Summary
|
LLY Eli Lilly and Company |
$1,392.09 -1.7% |
+12.0%
 |
orforglipron
Orforglipron for the treatment of obesity and overweight
|
|
11/10/2026 - Provided Update
Eli Lilly and Company announced the launch of Life Doesn't Slow Down, a new campaign for Lilly's Fo… Full Summary
|
JNJ Johnson & Johnson |
$276.08 -0.9% |
+8.7%
 |
CAPLYTA (Lumateperone)
Depressive Episodes associated with Bipolar
|
Phase 3
|
11/10/2026 - Pivotal Study
Johnson & Johnson announced that Study 452, the second pivotal Phase 3 study evaluating CAPLYTA (lu… Full Summary
|
LPCN Lipocine |
$1.55 -3.1% |
+1.3%
 |
LPCN 1154
Postpartum depression (PPD)
|
Phase 3
|
11/10/2026 - Dose Update
Lipocine Inc announced that the first participant has been dosed in BLOOM, the Company's Phase 3 stu… Full Summary
|
PALI Palisade Bio |
$0.96 -4.8% |
-28.2%
 |
PALI-2108
For patients affected by UC.
|
|
11/10/2026 - Provided Update
Palisade Bio, Inc. provided a business update highlighting continued execution of its Phase 2 clinic… Full Summary
|
MGX Metagenomi |
$0.65 +2.2% |
-20.5%
 |
MGX-001
Hemophilia A gene editing investigational therapy
|
|
11/10/2026 - FDA Clearance
Metagenomi Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has cleared… Full Summary
|
ATAI Atai Beckley |
$7.35
|
|
COMP360
Treatment-resistant depression
|
NDA
|
11/9/2026 - NDA submission
Compass Pathways plc announced the Company completed its submission of a New Drug Application (NDA)… Full Summary
|
VRDN Viridian Therapeutics |
$30.23 +0.6% |
+45.3%
 |
VRDN-008
treatment of rare and autoimmune diseases
|
Phase 1
|
11/9/2026 - Positive Results
Viridian Therapeutics, Inc y announced positive phase 1 results for VRDN-008. Full Summary
|
SPRB Spruce Biosciences |
$40.54 +0.1% |
+0.3%
 |
CRHX-101
for Congenital Adrenal Hyperplasia ("CAH")
|
|
11/9/2026 - Provided Update
Spruce Biosciences, Inc. announced that it has separated the company's CRHX-101 (formerly SPR-202)… Full Summary
|
COAG Hemab Therapeutics |
$39.79 +1.9% |
+24.0%
 |
HMB-001
in Glanzmann Thrombasthenia
|
Phase 3
|
11/9/2026 - Initiation
Hemab Therapeutics announced the initiation of SOLARA, a pivotal Phase 3 trial evaluating sutacimig… Full Summary
|
MANE Veradermics |
$124.32 -1.0% |
+1.9%
 |
VDPHL01
Patient Experiences With Pattern Hair Loss
|
Phase 2/3
|
11/9/2026 - Top-line results
Veradermics, Incorporated announced positive topline results from Part B of its randomized, double-… Full Summary
|
BLSM BlossomHill Therapeutics |
$14.66 -3.1% |
+3.5%
 |
BH-30643
Treatment of Advanced EGFR C797S-positive NSCLC
|
|
11/9/2026 - Outcome
BlossomHill Therapeutics, Inc. announced the outcome of its End-of-Phase 1 meeting with the U.S. F… Full Summary
|
ADAG Adagene |
$1.84 +24.0% |
-19.9%
 |
muzastotug
Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
|
|
11/9/2026 - Enrollment Update
Adagene Inc. announced completion of enrollment in its randomized Phase 2 dose-optimization trial … Full Summary
|
GLUE Monte Rosa Therapeutics |
$9.28 +2.3% |
-13.0%
 |
MRT-8102
For the treatment of inflammatory diseases
|
|
11/9/2026 - Presentation
Monte Rosa Therapeutics, Inc. announced the presentation of preclinical data showing that MRT-8102,… Full Summary
|
NKTX Nkarta |
$1.19 -5.2% |
-32.3%
 |
NKX019
Relapsed/refractory B cell malignancies
|
|
11/9/2026 - Initial Data
Nkarta announced positive initial clinical data from its Ntrust clinical trial program evaluating N… Full Summary
|
NVCR NovoCure |
$10.83 -2.8% |
-27.3%
 |
Optune Lua
For the Treatment of Metastatic Non-Small Cell Lung Cancer
|
|
11/9/2026 - Provided Update
Novocure announced today that it has received a Not Approvable Letter from the U.S. Food and Drug A… Full Summary
|
CYTK Cytokinetics |
$51.55 -0.2% |
-17.7%
 |
Aficamten
Symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
|
|
11/9/2026 - New Data
Cytokinetics, announced that new data related to aficamten were presented at the Hypertrophic Cardi… Full Summary
|
MNPR Monopar Therapeutics |
$70.85 -0.3% |
-0.9%
 |
ALXN1840 (tiomolibdate choline, TMC)
Wilson Disease
|
Phase 3
|
11/9/2026 - Presentation
Monopar Therapeutics Inc. announced the presentation of baseline data from the Phase 3 FoCus trial… Full Summary
|
ALLO Allogene Therapeutics |
$0.73 -2.2% |
-44.0%
 |
ALLO-329
For the Treatment of Autoimmune Diseases
|
|
11/9/2026 - Efficacy and Safety Data
Allogene Therapeutics, Inc. announced preliminary safety, efficacy and translational data from the… Full Summary
|
BIVI BioVie |
$0.98 -1.5% |
-28.5%
 |
Bezisterim
For Parkinson's Disease Patients
|
|
11/9/2026 - Findings Update
BioVie Inc. announced new biomarker findings from the ADDRESS-LC trial of bezisterim were presented … Full Summary
|
JANX Janux Therapeutics |
$10.40 -2.9% |
-37.9%
 |
JANX011
in Patients with Autoimmune Disease
|
Phase 1
|
11/9/2026 - Results
Janux Therapeutics, Inc announced initial clinical results from the Phase 1 study of JANX011 in he… Full Summary
|
HOWL Werewolf Therapeutics |
$1.04 -1.4% |
-0.5%
 |
WTX-124
Solid Tumors
|
|
11/9/2026 - Clinical Data
Werewolf Therapeutics, announced new clinical data from its Phase 1/1b clinical trial of WTX-124 a… Full Summary
|
PLYX Polaryx Therapeutics |
$1.65 +3.1% |
-14.1%
 |
PLX-200
For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis
|
|
11/9/2026 - Provided Update
Polaryx Therapeutics, Inc announces the activation of the first clinical trial site for SOTERIA, its… Full Summary
|
PLRX Pliant Therapeutics |
$0.65 -1.7% |
-27.8%
 |
PLN-101095
Inhibitor of αvβ8 and αvβ1 integrins in development for the treatment of solid tumors
|
|
11/9/2026 - Presentation
Pliant Therapeutics, Inc. announced the presentation of preclinical proof-of-concept data and new c… Full Summary
|
CRSP CRISPR Therapeutics |
$42.17 +5.0% |
-15.7%
 |
CTX310
Treatments for Cardiovascular Diseases
|
|
11/9/2026 - Data Presentation
CRISPR Therapeutics today presented clinical data from its Phase 1b clinical trial evaluating CTX310… Full Summary
|
MANE Veradermics |
$124.32 -1.0% |
+1.9%
 |
VDPHL01
Patient Experiences With Pattern Hair Loss
|
|
11/8/2026 - Provided Update
Veradermics, Incorporated announced it will host an investor call and live webcast on Monday, Novem… Full Summary
|
CRSP CRISPR Therapeutics |
$42.17 +5.0% |
-15.7%
 |
CTX112
In relapsed or refractory (R/R) CD19-positive B-cell malignancies
|
|
11/8/2026 - Provided Update
CRISPR Therapeutics today provided an update on zugocabtagene geleucel (zugo-cel; formerly CTX112™… Full Summary
|
CABA Cabaletta Bio |
$1.12 +9.3% |
-24.7%
 |
rese-cel
treatment for multiple autoimmune diseases
|
Phase 1/2
|
11/8/2026 - Clinical Data
Cabaletta Bio, Inc. announced new Phase 1/2 clinical data on resecabtagene autoleucel (rese-cel) to… Full Summary
|
ARWR Arrowhead Pharmaceuticals |
$43.46 +1.1% |
-24.1%
 |
plozasiran
In Patients with Familial Chylomicronemia Syndrome
|
|
11/7/2026 - Results
Arrowhead Pharmaceuticals, Inc. today presented results on two of the RNA interference (RNAi) base… Full Summary
|
JNJ Johnson & Johnson |
$276.08 -0.9% |
+8.7%
 |
Icotrokinra
For adults and adolescents with plaque psoriasis
|
Phase 3
|
11/7/2026 - Positive Results
Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotroki… Full Summary
|
ARGX argenex |
$946.12 -0.1% |
+14.6%
 |
VYVGART Hytrulo
Injection for Subcutaneous Use in Generalized Myasthenia Gravis
|
Phase 3
|
11/7/2026 - Data
argenx SE announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained impro… Full Summary
|
RARE Ultragenyx Pharmaceutical |
$17.58 +5.2% |
+16.6%
 |
UX111
For Sanfilippo syndrome type A (MPS IIIA)
|
UK MHRA
|
11/6/2026 - Provided Update
Ultragenyx announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) accepted… Full Summary
|
LLY Eli Lilly and Company |
$1,392.09 -1.7% |
+12.0%
 |
tirzepatide
For obesity or overweight with weight-related comorbidities, excluding type 2 diabetes.
|
|
11/6/2026 - Provided Update
Eli Lilly and Company and Hims & Hers Health, Inc. announced an agreement to help expand access to… Full Summary
|
MSLE Satellos Bioscience |
$6.26 +0.9% |
-2.9%
 |
BASECAMP
in boys ages 7, 8 or 9 with Duchenne muscular dystrophy (DMD).
|
|
11/6/2026 - Feedback
Satellos Bioscience Inc announced that, following feedback from the U.S. Food and Drug Administratio… Full Summary
|
IFRX InflaRx |
$1.10 -4.8% |
-24.5%
 |
Izicopan
small molecule inhibitor of the C5a receptor (C5aR)
|
|
11/6/2026 - Peer-reviewed publication
InflaRx N.V. announced the peer-reviewed publication of first-in-human Phase 1 clinical data for izi… Full Summary
|
PLSE Pulse Biosciences |
$45.06 +0.5% |
-5.2%
 |
nPulse™ Vybrance™
treatment of symptomatic and hyperfunctioning benign thyroid nodules (BTNs)
|
|
11/6/2026 - Results
Pulse Biosciences, Inc. announced interim six-month results from PRECISE-BTN, a prospective, multic… Full Summary
|
ASND Ascendis Pharma A/S |
$271.48 +0.1% |
+18.1%
 |
TransCon CNP
In Children with Achondroplasia
|
|
11/6/2026 - Positive Opinion
Ascendis Pharma A/S announced that the Committee for Orphan Medicinal Products (COMP) of the Europ… Full Summary
|